Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial

Isabelle Krämer, Stephan Stilgenbauer, Sascha Dietrich, Sebastian Böttcher, Matthias Zeis, Michael Stadler, Jörg Bittenbring, Lutz Uharek, Christof Scheid, Ute Hegenbart, Anthony Ho, Michael Hallek, Michael Kneba, Norbert Schmitz, Hartmut Döhner, Peter Dreger

Blood (2017) 130 (12): 1477–1480.

https://doi.org/10.1182/blood-2017-04-775841

Published: 2017

Includes: Supplemental data

Journal Articles

Impact of Immune Reconstitution (IR) and Graft-Versus-Host Disease (GvHD) on Clinical Outcomes after Treatment with Donor T Cells Transduced to Express the Herpes Simplex Virus Thymidine-Kinase Suicide Gene (TK cells) in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)

Blood (2016) 128 (22): 4599.

https://doi.org/10.1182/blood.V128.22.4599.4599

Published: 2016

Journal Articles

Long Term Follow up of the AML97-Study for Patients with AML Older Than 60 Years: A Study of the East German Hematology and Oncology Study Group (OSHO)

Blood (2014) 124 (21): 3664.

https://doi.org/10.1182/blood.V124.21.3664.3664

Published: 2014

Journal Articles

Minimum Tolerable Interval of Radioimmunotherapy and Autologous Stem Cell Transplantation after High-Dose Chemotherapy for Relapsed or Refractory Aggressive B Cell Non-Hodgkin-Lymphoma Provides Excellent Disease Control

Justin Hasenkamp, MD, Georg Hess, MD, Bernd Hertenstein, MD, Mathias Witzens-Harig, MD, Lutz Uharek, MD, Martin Gramatzki, MD, Michael Pfreundschuh, Gerald Wulf, MD, Lorenz H. Truemper, MD PhD, Norbert Schmitz, MD, Bertram Glass, MD

Blood (2014) 124 (21): 3986.

https://doi.org/10.1182/blood.V124.21.3986.3986

Published: 2014

Journal Articles

Infusion of Donor Lymphocytes Genetically Engineered to Express the Herpes Simplex Virus Thymidine Kinase (HSV-TK) Suicide Gene after Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Preliminary Efficacy Data from the Randomized TK008 Study

Blood (2014) 124 (21): 2535.

https://doi.org/10.1182/blood.V124.21.2535.2535

Published: 2014

Journal Articles

Haploidentical Second Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Acute Leukemia Relapse after First Allo-HSCT: A Retrospective Registry Analysis of 60 Patients on Behalf of the German Cooperative Transplant Group

Maximilian Christopeit, MD, Johanna Tischer, MD, Martin Bornhäuser, MD, Lutz Uharek, MD, Christian Pfrepper, Gerhard Behre, MD, Dietger Niederwieser, MD, Nicolaus Kröger, MD, Wolf Rösler, MD, Stefan A. Klein, Dietrich Beelen, MD, Andreas Hausmann, MD, Wolfgang Bethge, MD, Christoph Schmid, MD

Blood (2014) 124 (21): 2590.

https://doi.org/10.1182/blood.V124.21.2590.2590

Published: 2014

Journal Articles

Telomere Lenght and Outcome of Allogeneic Stem Cell Transplantation for Poor Risk Chronic Lymphocytic Leukemia: Results from the GCLLSG CLL3X Trial

Annika Scheffold, MSc, Billy Michael Chelliah Jebaraj, PhD, Eugen Tausch, MD, Sebastian Boettcher, MD, Matthias Ritgen, Donald Bunjes, MD, Matthias Zeis, MD, Michael Stadler, MD, Lutz Uharek, MD, Christof Scheid, MDPhD, Ute Hegenbart, MD, Michael Hallek, MD, Michael Kneba, MD PhD, Norbert Schmitz, MD PhD, Hartmut Doehner, MD, Peter Dreger, MD, Stephan Stilgenbauer, MD

Blood (2014) 124 (21): 1951.

https://doi.org/10.1182/blood.V124.21.1951.1951

Published: 2014

Journal Articles

Single Nucleotide Polymorphisms Within The Thrombomodulin Gene (THBD) Predict Risk Of Non-Relapse Mortality In Patients With Graft-Versus-Host Disease

Thomas Luft, MD, PhD, Olaf Penack, MD, Olga Blau, MD, PhD, Sascha Dietrich, MD, Berend H. Isermann, MD, Anthony D Ho, MD, Lutz Uharek, Peter Dreger, MD, Rajive Kumar, PhD, Krishna P.S. Rachakonda, PhD

Blood (2013) 122 (21): 4589.

https://doi.org/10.1182/blood.V122.21.4589.4589

Published: 2013

Journal Articles

Azacitidine and Donor Lymphocyte Infusions As Treatment For Relapse After Allogeneic Stem Cell Transplantation - a Retrospective Multicenter Analysis In 115 Patients On Behalf Of The German Cooperative Transplant Study Group

Blood (2013) 122 (21): 4642.

https://doi.org/10.1182/blood.V122.21.4642.4642

Published: 2013

Journal Articles

TP53 , SF3B1 , and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial

Blood (2013) 121 (16): 3284–3288.

https://doi.org/10.1182/blood-2012-11-469627

Published: 2013

Includes: Supplemental data

Journal Articles

Salvage Therapy with Azacitidine Increases Regulatory T Cells in Patients with AML or MDS and Early Relapse After Allogeneic Blood Stem Cell Transplantation

Thomas Schroeder, MD, Julia Fröbel, Ron Patrick Cadeddu, Akos G. Czibere, MD, Ariane Dienst, Esther Zipperer, MD, Uwe Platzbecker, MD, Gesine Bug, Lutz Uharek, MD, Roland Fenk, MD, Ulrich Germing, Nicolaus Kröger, Rainer Haas, MD, Guido Kobbe, MD

Blood (2012) 120 (21): 1964.

https://doi.org/10.1182/blood.V120.21.1964.1964

Published: 2012

Journal Articles

SF3B1 , NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial

Peter Dreger, MD, Andrea Schnaiter, MD, Marianna Rossi, Peter Paschka, Andreas Bühler, MD, Thorsten Zenz, MD, Sascha Dietrich, MD, Sebastian Böttcher, MD, Donald Bunjes, Michael Stadler, MD, Lutz Uharek, MD, Christof Scheid, MD, PhD, Ute Hegenbart, MD, Michael Hallek, MD, Michael Kneba, MD, PhD, Norbert Schmitz, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2012) 120 (21): 966.

https://doi.org/10.1182/blood.V120.21.966.966

Published: 2012

Journal Articles

Phase II Study of Azacitidine (Vidaza®, Aza) and Donor Lymphocyte Infusions (DLI) As First Salvage Therapy in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (allo-SCT): Final Results From the AZARELA-Trial (NCT-00795548)

Thomas Schroeder, MD, Akos Czibere, MD, PhD, Nicolaus Kröger, Uwe Platzbecker, MD, Gesine Bug, Lutz Uharek, Prof., Dr., Thomas Luft, Christine Wolschke, Ingmar Bruns, MD, Fabian Zohren, MD, Roland Fenk, Rainer Haas, MD, Prof, Guido Kobbe, MD

Blood (2011) 118 (21): 656.

https://doi.org/10.1182/blood.V118.21.656.656

Published: 2011

Journal Articles

Long Term Follow-up of the Prospective Multicenter Study of reduced-Intensity Allogeneic Stem Cell Transplantation for Primary or Post ET/PV Myelofibrosis

Blood (2011) 118 (21): 1019.

https://doi.org/10.1182/blood.V118.21.1019.1019

Published: 2011

Journal Articles

Organ Siderosis In a Murine Graft-Versus-Host-Model After Allogeneic Stem Cell Transplantations Unrelated to Red Cell Transfusion

Axel Nogai, Dr., Reinhard Ziebig, Dr., Martina U. Muckenthaler, Prof., PhD, Eckhard Thiel, Prof., Dr., Dr., h.c., Lutz Uharek, Prof., Dr., Michael Notter, Dr.

Blood (2010) 116 (21): 2048.

https://doi.org/10.1182/blood.V116.21.2048.2048

Published: 2010

Journal Articles

Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)

Blood (2010) 116 (21): 1376.

https://doi.org/10.1182/blood.V116.21.1376.1376

Published: 2010

Journal Articles

DMSO Reduction Strategies Reduce DMSO Induced Post Autologous Transplant Morbidity In Patients with Lymphoma and Myeloma –Results from an EBMT Non Interventional Prospective Study

Curly TCM Morris, Marijke Scholten, Liesbeth de Wreede, Anja van Biezen, Ebbe Dickmeiss, Marek Trneny, Jane F. Apperley, Patrizia Chiusolo, Gustaaf Van Imhoff, MD, PhD, Stig Lenhoff, MD, PhD, Lutz Uharek, Giovanni Martinelli, MD, Marcus Hentrich, MD, Anna Sureda, MD, PhD, Theo M de Witte, Tapani Ruutu, MD

Blood (2010) 116 (21): 2397.

https://doi.org/10.1182/blood.V116.21.2397.2397

Published: 2010

Journal Articles

Successful Treatment of High-Risk and Refractory Acute Myeloid Leukemia with haploidentical Stem Cell Transplantation Plus NK cell therapy

Lutz Uharek, MD, Birte Friedrichs, MD, Axel Nogai, MD, Chiara Gentilini, MD, Nadezda Basara, MD, Dietger Niederwieser, MD, Eckhard Thiel, MD

Blood (2010) 116 (21): 2370.

https://doi.org/10.1182/blood.V116.21.2370.2370

Published: 2010

Journal Articles

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

Blood (2010) 116 (14): 2438–2447.

https://doi.org/10.1182/blood-2010-03-275420

Published: 2010

Includes: Supplemental data

Journal Articles

Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study

Wolfgang A. Bethge, Thoralf Lange, Christoph Meisner, Stephanie von Harsdorf, Martin Bornhaeuser, Birgit Federmann, Michael Stadler, Lutz Uharek, Matthias Stelljes, Stefan Knop, Gerald Wulf, Rudolf Trenschel, Vladan Vucinic, Helmut Dittmann, Christoph Faul, Wichard Vogel, Lothar Kanz, Donald Bunjes

Blood (2010) 116 (10): 1795–1802.

https://doi.org/10.1182/blood-2010-02-270538

Published: 2010

NARROW

Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial

Long Term Follow up of the AML97-Study for Patients with AML Older Than 60 Years: A Study of the East German Hematology and Oncology Study Group (OSHO)

Minimum Tolerable Interval of Radioimmunotherapy and Autologous Stem Cell Transplantation after High-Dose Chemotherapy for Relapsed or Refractory Aggressive B Cell Non-Hodgkin-Lymphoma Provides Excellent Disease Control

Infusion of Donor Lymphocytes Genetically Engineered to Express the Herpes Simplex Virus Thymidine Kinase (HSV-TK) Suicide Gene after Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Preliminary Efficacy Data from the Randomized TK008 Study

Haploidentical Second Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Acute Leukemia Relapse after First Allo-HSCT: A Retrospective Registry Analysis of 60 Patients on Behalf of the German Cooperative Transplant Group

Telomere Lenght and Outcome of Allogeneic Stem Cell Transplantation for Poor Risk Chronic Lymphocytic Leukemia: Results from the GCLLSG CLL3X Trial

Single Nucleotide Polymorphisms Within The Thrombomodulin Gene (THBD) Predict Risk Of Non-Relapse Mortality In Patients With Graft-Versus-Host Disease

Azacitidine and Donor Lymphocyte Infusions As Treatment For Relapse After Allogeneic Stem Cell Transplantation - a Retrospective Multicenter Analysis In 115 Patients On Behalf Of The German Cooperative Transplant Study Group

TP53 , SF3B1 , and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial

Salvage Therapy with Azacitidine Increases Regulatory T Cells in Patients with AML or MDS and Early Relapse After Allogeneic Blood Stem Cell Transplantation

SF3B1 , NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial

Long Term Follow-up of the Prospective Multicenter Study of reduced-Intensity Allogeneic Stem Cell Transplantation for Primary or Post ET/PV Myelofibrosis

Organ Siderosis In a Murine Graft-Versus-Host-Model After Allogeneic Stem Cell Transplantations Unrelated to Red Cell Transfusion

Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)

DMSO Reduction Strategies Reduce DMSO Induced Post Autologous Transplant Morbidity In Patients with Lymphoma and Myeloma –Results from an EBMT Non Interventional Prospective Study

Successful Treatment of High-Risk and Refractory Acute Myeloid Leukemia with haploidentical Stem Cell Transplantation Plus NK cell therapy

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only